126 related articles for article (PubMed ID: 10458245)
1. CD56 expression in acute promyelocytic leukemia: a possible indicator of poor treatment outcome?
Murray CK; Estey E; Paietta E; Howard RS; Edenfield WJ; Pierce S; Mann KP; Bolan C; Byrd JC
J Clin Oncol; 1999 Jan; 17(1):293-7. PubMed ID: 10458245
[TBL] [Abstract][Full Text] [Related]
2. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of CD56 antigen expression in acute myeloid leukemia.
Di Bona E; Sartori R; Zambello R; Guercini N; Madeo D; Rodeghiero F
Haematologica; 2002 Mar; 87(3):250-6. PubMed ID: 11869936
[TBL] [Abstract][Full Text] [Related]
4. Aberrant phenotypic expression of CD15 and CD56 identifies poor prognostic acute promyelocytic leukemia patients.
Breccia M; De Propris MS; Minotti C; Stefanizzi C; Raponi S; Colafigli G; Latagliata R; Guarini A; Foà R
Leuk Res; 2014 Feb; 38(2):194-7. PubMed ID: 24296270
[TBL] [Abstract][Full Text] [Related]
5. Acute promyelocytic leukemia is a distinct subset of acute myelocytic leukemia with unique clinicopathologic characteristics including longer duration of relapse free survival: experience in 13 cases.
Lee KH; Kim DH; Lee JS; Suh CW; Kim SW; Kim SB; Lee JH; Doh BS; Chi HS; Lee MS
J Korean Med Sci; 1994 Dec; 9(6):437-43. PubMed ID: 7786438
[TBL] [Abstract][Full Text] [Related]
6. [Clinical and laboratory features of patients with CD34(+) acute promyelocytic leukemia].
Liang JY; Wu DP; Liu YJ; Ma QF; Xue YQ; Zhu MQ; Chen ZX
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):196-8. PubMed ID: 19615259
[TBL] [Abstract][Full Text] [Related]
7. Clinical and biological significance of CD56 antigen expression in acute promyelocytic leukemia.
Ito S; Ishida Y; Oyake T; Satoh M; Aoki Y; Kowata S; Uchiyama T; Enomoto S; Sugawara T; Numaoka H; Suzuki K; Murai K
Leuk Lymphoma; 2004 Sep; 45(9):1783-9. PubMed ID: 15223636
[TBL] [Abstract][Full Text] [Related]
8. CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome.
Raspadori D; Damiani D; Michieli M; Stocchi R; Gentili S; Gozzetti A; Masolini P; Michelutti A; Geromin A; Fanin R; Lauria F
Haematologica; 2002 Nov; 87(11):1135-40. PubMed ID: 12414342
[TBL] [Abstract][Full Text] [Related]
9. High incidence of CD56 expression and relapse rate in acute myeloid leukemia patients with t(8;21) in Taiwan.
Hsiao CH; Tang JL; Yao M; Tsay W; Wang CH; Chen YC; Shen MC; Tien HF
J Formos Med Assoc; 2002 Jun; 101(6):393-8. PubMed ID: 12189644
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors in acute promyelocytic leukemia: strategies to define high-risk patients.
Testa U; Lo-Coco F
Ann Hematol; 2016 Apr; 95(5):673-80. PubMed ID: 26920716
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
[TBL] [Abstract][Full Text] [Related]
12. [The clinical and laboratory features of acute promyelocytic leukemia: an analysis of 513 cases].
Liang JY; Wu DP; Liu YJ; Ma QF; Gong JX; Zhu MQ; Xue YQ; Chen ZX
Zhonghua Nei Ke Za Zhi; 2008 May; 47(5):389-92. PubMed ID: 18953948
[TBL] [Abstract][Full Text] [Related]
13. CD2+ acute promyelocytic leukemia is associated with leukocytosis, variant morphology and poorer prognosis.
Kaito K; Katayama T; Masuoka H; Nishiwaki K; Sano K; Sekiguchi N; Hagino T; Kobayashi M
Clin Lab Haematol; 2005 Oct; 27(5):307-11. PubMed ID: 16178910
[TBL] [Abstract][Full Text] [Related]
14. Clinical characteristics, prognostic factors and multidrug-resistance related protein expression in 36 adult patients with acute promyelocytic leukemia.
Candoni A; Damiani D; Michelutti A; Masolini P; Michieli M; Michelutti T; Geromin A; Fanin R
Eur J Haematol; 2003 Jul; 71(1):1-8. PubMed ID: 12801292
[TBL] [Abstract][Full Text] [Related]
15. Secondary acute promyelocytic leukemia. Characteristics and prognosis of 14 patients from a single institution.
Pollicardo N; O'Brien S; Estey EH; al-Bitar M; Pierce S; Keating M; Kantarjian HM
Leukemia; 1996 Jan; 10(1):27-31. PubMed ID: 8558933
[TBL] [Abstract][Full Text] [Related]
16. Acute promyelocytic leukemia M3: cytomorphologic, immunophenotypic, cytogenetic, and molecular variants.
Sucić M; Zadro R; Burazer B; Labar B; Nemet D; Mrsić M; Aurer I; Mrsić S; Hitrec V; Boban D; Marković-Glamocak M; Batinić D; Uzarević B; Stavljenić-Rukavina A
J Hematother Stem Cell Res; 2002 Dec; 11(6):941-50. PubMed ID: 12590709
[TBL] [Abstract][Full Text] [Related]
17. A survival study and prognostic factors analysis on acute promyelocytic leukemia at a single center.
Xin L; Wan-jun S; Zeng-jun L; Yao-zhong Z; Yun-tao L; Yan L; Chang-chun W; Qiao-chuan L; Ren-chi Y; Ming-zhe H; Jian-xiang W; Lu-gui Q
Leuk Res; 2007 Jun; 31(6):765-71. PubMed ID: 17007927
[TBL] [Abstract][Full Text] [Related]
18. Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.
Elliott MA; Letendre L; Tefferi A; Hogan WJ; Hook C; Kaufmann SH; Pruthi RK; Pardanani A; Begna KH; Ashrani AA; Wolanskyj AP; Al-Kali A; Litzow MR
Eur J Haematol; 2012 Mar; 88(3):237-43. PubMed ID: 22023492
[TBL] [Abstract][Full Text] [Related]
19. Management of acute promyelocytic leukemia relapse in the ATRA era.
Castagnola C; Lunghi M; Corso A; Tajana M; Zappasodi P; Dabusti M; Lazzarino M; Bernasconi C
Haematologica; 1998 Aug; 83(8):714-7. PubMed ID: 9793255
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
